Related by context. All words. (Click for frequent words.) 82 HGS ETR2 76 mapatumumab 76 alvespimycin 76 IMC A# 75 PXD# 75 ganetespib 75 lintuzumab 75 Panzem R NCD 74 OXi# 74 RGB # 74 forodesine 74 HGS# 74 OncoVEX GM CSF 73 INCB# [001] 73 CR# vcMMAE 73 elotuzumab 73 HGS ETR1 mapatumumab 72 MGCD# [001] 72 OMP #M# 72 AEG# 72 evaluating tivozanib 72 pertuzumab 72 HER2 positive metastatic breast 72 oral prodrug 72 GRN#L 72 phase IIb clinical 72 Phase 1b 71 enzastaurin 71 Omacetaxine 71 huC# DM4 71 Perifosine 71 erlotinib Tarceva ® 71 IMA# 71 Sym# 71 seliciclib 71 IMC #B 71 Bezielle 71 Phase Ib II 71 Phase 2a trial 71 R#/MEM # 71 Allovectin 7 R 70 MAGE A3 ASCI 70 PEG SN# 70 Azedra 70 trastuzumab Herceptin R 70 Phase Ib clinical trials 70 velafermin 70 TELCYTA 70 SAR# [004] 70 CBLC# 70 DAVANAT 70 axitinib 70 HuLuc# 70 CCX# 70 AP# [003] 70 Phase Ib study 70 sapacitabine 70 glufosfamide 70 Imprime PGG 70 BRIM2 70 PSMA ADC 70 Cloretazine ® 70 sorafenib Nexavar ® 70 MEK inhibitor RDEA# 70 custirsen 70 ALN VSP 70 neratinib 70 XL# [003] 70 valopicitabine 70 belinostat 70 XmAb# 70 PRT# 70 MDV# 70 refractory chronic lymphocytic 70 TTF Therapy 70 talactoferrin 70 tanespimycin 70 metaglidasen 70 HCD# [002] 70 adecatumumab 70 antitumor activity 69 phase Ib 69 Phase Ib 69 cilengitide 69 Exherin TM 69 Xanafide 69 docetaxel chemotherapy 69 docetaxel Taxotere R 69 pomalidomide 69 ENMD # 69 imetelstat 69 CA4P 69 dacetuzumab 69 Bortezomib 69 obatoclax 69 registrational trial 69 Aflibercept 69 TACI Ig 69 AQ4N 69 MEK inhibitor 69 Azixa 69 BiTE antibody 69 dasatinib Sprycel ® 69 CYT# potent vascular disrupting 69 PNP inhibitor 69 ELACYT 69 HspE7 69 virus HCV protease inhibitor 69 MGd 69 Alocrest 69 RDEA# 69 bevacizumab Avastin ® 69 nab paclitaxel 69 GAP #B# 69 AEGR 69 NXL# 69 antibody MAb 69 oral ridaforolimus 69 deforolimus 69 anti leukemic 69 voreloxin 69 pralatrexate 69 ongoing Phase 1b 69 Seliciclib 69 BRIM3 69 Randomized Phase 69 CYC# 69 Phase #b/#a clinical 69 CD# CEA 69 FOLFOX6 chemotherapy regimen 69 receptor tyrosine kinase inhibitor 69 relapsed multiple myeloma 69 metastatic castration resistant 68 DXL# 68 darapladib 68 Traficet EN 68 MyVax R 68 anti EGFR antibody 68 Tarvacin TM 68 Ceflatonin 68 Amigal 68 TELINTRA 68 CORT # 68 Blinatumomab 68 YONDELIS 68 hematological cancers 68 ofatumumab 68 celgosivir 68 Voreloxin 68 rindopepimut 68 PDX pralatrexate 68 MEK inhibitors 68 Epothilone D 68 PS# [001] 68 generation Hsp# inhibitor 68 Elotuzumab 68 HuMax EGFr 68 dose cohorts 68 Phase #/#a trial 68 PEG Interferon lambda 68 elacytarabine 68 investigational monoclonal antibody 68 CIMZIA TM 68 Annamycin 68 RG# [001] 68 TOCOSOL Paclitaxel 68 pharmacokinetic PK study 68 Tyrima 68 phase IIa clinical 68 Panzem NCD 68 BAY #-# 68 sorafenib tablets 68 Phase 1b trial 68 alkylating agent 68 eniluracil 68 blinatumomab 68 CoFactor 68 EOquin TM 68 HuMax CD4 68 Proxinium TM 68 castration resistant prostate cancer 67 rNAPc2 67 JAK inhibitor 67 Symadex 67 thymalfasin 67 motesanib 67 milatuzumab 67 preclinically 67 EndoTAG TM -1 67 MT# MEDI 67 farletuzumab 67 castrate resistant prostate cancer 67 otelixizumab 67 oral picoplatin 67 Phase Ib clinical 67 CD# antibody [001] 67 Amrubicin 67 orally bioavailable 67 CTAP# Capsules 67 trastuzumab DM1 T DM1 67 evaluating Xcytrin 67 Archexin 67 IMGN# 67 MET amplification 67 systemic RNAi therapeutic 67 FOLOTYN ® 67 L BLP# 67 lumiliximab 67 initiate Phase 1b 67 targeting CD# 67 PDE4 inhibitor 67 PLK1 SNALP 67 LymphoStat B 67 Allovectin 7 67 Aplidin 67 XL# XL# 67 EGFR TKI 67 EOquin 67 Epratuzumab 67 decitabine 67 picoplatin 67 talabostat 67 leukemia AML 67 fosbretabulin 67 protein kinase inhibitor 67 PSN# [002] 67 novel VDA molecule 67 hematological malignancies 67 MT#/MEDI-# 67 tezampanel 67 5 FU leucovorin 67 ASONEP 67 JAK1 67 perifosine 67 imatinib Gleevec ® 67 interferon gamma 1b 67 refractory AML 67 Allovectin 7 ® 67 Exelixis compounds 67 PRTX 67 Sapacitabine 67 viral kinetics 67 TREANDA 67 Chemophase 67 carboplatin paclitaxel 67 Capesaris 67 dose escalation 67 radiation sensitizer 67 HuMax CD# 67 lintuzumab SGN 67 APOPTONE 67 systemically administered 67 multicenter Phase 67 favorable pharmacokinetic profile 67 maximally tolerated dose 67 TG# [003] 67 Quinamed 67 GRN# 67 selective androgen receptor modulator 67 HSP# inhibitor 67 Glufosfamide 67 galiximab 67 VEGFR2 inhibitor 67 CEQ# 67 orally administered inhibitor 67 AVE# 67 Pralatrexate 67 cetuximab Erbitux ® 66 FOLOTYN 66 ApoB SNALP 66 elagolix 66 cancer immunotherapies 66 cell lymphoma CTCL 66 dose escalation trial 66 XL# XL# XL# XL# 66 nilotinib Tasigna ® 66 Zybrestat 66 Carfilzomib 66 atacicept 66 Hsp# Inhibitor 66 Cloretazine R VNP#M 66 ascending dose 66 SUCCEED trial 66 gefitinib Iressa 66 histone deacetylase HDAC inhibitor 66 Phase IIb trials 66 CTA# Injection 66 bortezomib Velcade R 66 bendamustine 66 gemcitabine chemotherapy 66 pegylated interferon alfa 2a 66 CLORETAZINE TM VNP#M 66 NGX# 66 Aurora kinase 66 IRX 2 66 refractory multiple myeloma 66 oral deforolimus 66 ZK EPO 66 Protexia R 66 IAP inhibitor 66 Telintra 66 telaprevir VX 66 Hsp# inhibition 66 K ras mutations 66 vidofludimus 66 5 fluorouracil leucovorin 66 GVAX 66 alpha folate receptor 66 tesmilifene 66 dose cohort 66 HCV protease 66 investigational humanized monoclonal antibody 66 LymphoStat B TM 66 SCH # 66 Xcytrin R 66 INGN 66 TBC# 66 sodium glucose cotransporter 66 Insegia 66 vandetanib 66 including eniluracil ADH 66 Phase 2b Clinical Trial 66 Personalized Immunotherapy 66 subcutaneous formulation 66 elesclomol 66 mertansine 66 ZYBRESTAT 66 Hsp# inhibitor 66 Vicinium TM 66 TOCOSOL Camptothecin 66 dasatinib Sprycel 66 metastatic renal cell carcinoma 66 standard chemotherapy regimen 66 phase IIb 66 Trofex 66 FOLFOX chemotherapy 66 ALN PCS 66 AAG geldanamycin analog 66 KRN# 66 FOLFOX6 66 xenograft models 66 PF # [001] 66 MGCD# [002] 66 liposomal formulation 66 sorafenib Nexavar 66 nucleoside analog 66 Nanobody 66 PEGylated Fab fragment 66 EGFR HER2 66 OvaRex R 66 compound INCB# 66 velafermin belinostat 66 Virulizin ® 66 VNP#M 66 PLX# 66 PANVAC VF 66 pharmacodynamic effects 66 imatinib therapy 66 MKC# MT 66 adecatumumab MT# 66 low dose cytarabine 66 ALN TTR 66 candidate CRLX# 66 ZOLINZA 66 evaluating picoplatin 66 JAK inhibitors 66 mGluR5 negative 66 phase IIb trial 66 leading oral taxane 66 Cloretazine 66 Actilon 66 MYDICAR ® 66 Pivotal Phase 66 HCV SPRINT 66 humanized anti 66 relapsed MM 66 bortezomib 66 ENMD 66 MCSP respectively 66 EFAPROXYN 66 Phase III Pivotal 66 Ozarelix 66 GALNS 66 KNS # 66 recurrent NSCLC 66 DAVANAT R 66 INCB# [002] 65 RAV# 65 visilizumab 65 Cotara 65 Dapagliflozin 65 iniparib 65 CCR5 mAb 65 registrational 65 Targretin 65 leukemia CLL 65 depsipeptide 65 NVA# 65 irinotecan doxorubicin oxaliplatin paclitaxel 65 MOZOBIL 65 IIa trial 65 tremelimumab 65 sunitinib malate 65 entinostat 65 cediranib 65 refractory gout 65 Phase 2a 65 urocortin 2 65 ISIS # 65 cMET 65 Panitumumab 65 metastatic hormone refractory 65 CDK inhibitor 65 Phase 2b trial 65 dacarbazine 65 BRAF inhibitor 65 lenalidomide Revlimid R 65 Cannabinor 65 Reolysin 65 confirmatory Phase III 65 MEK Inhibitor 65 lesinurad 65 small molecule defensin 65 XL# XL# XL# 65 ISTODAX 65 DermaVir Patch 65 OMP #R# 65 Folfox 65 telomerase inhibitor drug 65 BCX# 65 systemic anaplastic large 65 Ofatumumab 65 romidepsin 65 ixabepilone 65 phase IIb study 65 Irinotecan 65 ocrelizumab 65 CRLX# 65 Curaxin CBLC# 65 TRV# [001] 65 Antitumor Activity 65 Pegasys ® 65 Stedivaze 65 ALN TTR# 65 recurrent metastatic ovarian cancer 65 Asentar 65 systemic ALCL 65 teduglutide 65 Atiprimod 65 Phase 2b study 65 FOLFIRI 65 LY# [003] 65 docetaxel Taxotere ® 65 Vaxfectin TM 65 vascular disrupting agent 65 dose limiting toxicities 65 JAK2 inhibitor 65 LE DT 65 PEGPH# 65 GSK # 65 Trastuzumab 65 AeroLEF TM 65 Enzastaurin 65 TNFerade 65 phase 2a 65 dependent kinase inhibitor 65 multicenter Phase II 65 Elagolix 65 TLK# 65 riociguat 65 TRO# 65 IL# PE#QQR 65 pharmacodynamic PD 65 PI3K/Akt pathway inhibitor 65 Tesetaxel 65 teriflunomide 65 Azedra TM 65 huN# DM1 65 Thiarabine 65 PI3K inhibitor 65 ruxolitinib 65 GLP toxicology studies 65 sunitinib Sutent ® 65 PKC# 65 Troxatyl 65 pan HDAC inhibitor 65 JVRS 65 #D#C# 65 dose escalation Phase 65 LymphoStat B belimumab 65 gemcitabine Gemzar 65 ASA# 65 IAP inhibitors 65 aflibercept 65 refractory cutaneous T 65 nucleotide analog 65 BZL# 65 APTIVUS r 65 Romidepsin 65 Vitaxin 65 limiting toxicity 65 EGFR inhibitors 65 dosing cohort 65 cetuximab Erbitux R 65 heavily pretreated 65 anti CTLA 65 ularitide 65 pegylated liposomal doxorubicin 65 AVN# [001] 65 volociximab 65 Marqibo 65 LEP ETU 65 Gleevec resistant 65 phase IIa 65 Aurexis 65 Genasense ® oblimersen 65 antibody MT# 65 telaprevir dosed 65 estramustine 65 Dacogen injection 65 Hepatocellular Carcinoma HCC 65 mGluR5 NAM 65 evaluating satraplatin 65 HDAC Inhibitor 65 refractory metastatic 65 agonistic human 65 ARRY # 65 telomerase therapeutic 65 Phase #b/#a 65 bafetinib 65 pharmacokinetic PK 65 hematologic malignancies 65 XL# anticancer compounds 65 ProLindac 65 GRNVAC1 65 ARRY 65 hematological tumors 65 ImmunoVEX HSV2 65 resminostat 65 Metastatic Melanoma 65 platinum refractory 65 Tamibarotene 65 Solazed TM 65 paclitaxel Taxol ® 65 TMC# [002] 65 vicriviroc 65 Bavituximab 65 AKT inhibitor 65 recurrent glioblastoma multiforme 65 sorafenib Nexavar R 65 prostate cancer CRPC 65 IDX# 65 omega interferon 65 TRAIL receptor antibodies 65 PROSTVAC VF 65 T#I mutation 65 rhIGFBP 3 65 immunomodulator 65 standard chemotherapy regimens 65 refractory NSCLC 64 #ME# 64 drug conjugate 64 olaparib 64 cetuximab Erbitux 64 relapsed refractory multiple myeloma 64 MAXY G# 64 Cetrorelix 64 alpha 2a 64 vinca alkaloid 64 sunitinib 64 Phase IIa trial 64 alfa 2a 64 ONCONASE 64 mRCC 64 Panzem R 64 tezampanel NGX# 64 Pimavanserin 64 stage IIIB 64 PD LID 64 proteasome inhibitor 64 sodium thiosulfate STS 64 pradefovir 64 novel tubulin binding 64 CCR9 antagonist 64 metastatic colorectal 64 Phase #b/#a trial 64 delta isoform 64 solid tumors 64 Phase 2a clinical trials 64 squalamine 64 epothilone 64 randomized Phase 64 ALN RSV# 64 Ophena TM 64 unique alkylating agent 64 ThermoDox R 64 androgen independent 64 LUX Lung 64 mitogen activated ERK kinase 64 posaconazole 64 taxane 64 NEUMUNE 64 Pertuzumab 64 aflibercept VEGF Trap 64 metastatic RCC 64 OncoVEX 64 iSONEP 64 Fludara 64 Viramidine 64 administered subcutaneously 64 crizotinib PF # 64 Clolar ® 64 oral proteasome inhibitor 64 Aplidin R 64 panobinostat 64 sodium Injection 64 nonclinical studies 64 lapatinib Tykerb 64 Genasense ® 64 Zolinza 64 demonstrated antitumor activity 64 Nexavar ® 64 Tarceva TM 64 REOLYSIN ® 64 polymerase inhibitor 64 DU #b 64 targeted radiotherapeutic 64 TYZEKA 64 Amplimexon 64 Akt inhibitor 64 anticancer agents 64 nitazoxanide 64 imatinib resistant 64 EGFR expressing mCRC 64 Phase #/#a 64 Vidaza ® 64 ozarelix 64 IMP# 64 amrubicin 64 R roscovitine CDK cyclin 64 metastatic castrate resistant 64 HRPC 64 Solazed 64 Ostarine 64 azacitidine 64 KRAS mutations occur 64 PRX # 64 2 methoxyestradiol 64 modified glutathione analog 64 eprotirome 64 lead Aganocide compound 64 pegylated interferon alpha 64 Omacetaxine mepesuccinate 64 idarubicin 64 Valortim R 64 BiTE R 64 Phase 2a clinical 64 Genasense oblimersen sodium Injection 64 SinuNase TM 64 Genz # 64 AZD# 64 AzaSite Plus 64 oncolytic 64 Dasatinib 64 placebo controlled Phase 64 investigational pan BCR 64 PRX# 64 anticancer compound 64 evaluating T DM1 64 tumors GIST 64 daclizumab 64 fluoropyrimidine 64 Plicera 64 vinorelbine 64 R sorafenib tablets 64 tolerated dose MTD 64 HDACi 64 GVAX ® 64 tolevamer 64 oxidative stress inducer 64 IV metastatic melanoma 64 multiple ascending dose 64 Talabostat 64 dextromethorphan quinidine 64 APTIVUS 64 CYT# 64 dasatinib 64 ponatinib 64 eltrombopag 64 cannabinor 64 tubulin inhibitor 64 non nucleoside inhibitor 64 temsirolimus 64 nucleoside reverse transcriptase inhibitor 64 TRIOLEX 64 Copegus ribavirin 64 DEB# 64 R# #mg BID 64 INCB# [003] 64 selective kinase inhibitor 64 glioblastoma multiforme GBM 64 Hematide ™ 64 refractory CLL 64 CD# monoclonal antibody 64 unresectable stage 64 signal transduction inhibitor 64 PCK# 64 radezolid 64 HCV protease inhibitor 64 Lenocta 64 Phase IIb clinical trials 64 Serdaxin ® 64 dose escalation clinical 64 goserelin 64 Hedgehog Pathway Inhibitor 64 metastatic CRC 64 rALLy clinical trial 64 QLT# 64 Darinaparsin 64 Daclizumab 64 IgG1 monoclonal antibody 64 vemurafenib 64 Multimeric 64 Panzem 64 Golimumab 64 hA# 64 GMX# 64 sorafenib 64 Fc engineered 64 bevirimat 64 Gemzar ® 64 Xelox 64 MAGE A3 64 Cethromycin 63 refractory acute myeloid 63 multi kinase inhibitor 63 gemcitabine cisplatin 63 antiviral activity 63 plus dacarbazine 63 viral kinetic 63 TOLAMBA 63 cisplatin vinorelbine 63 Pegasys R 63 alvimopan 63 CD4 monoclonal antibody 63 Ixempra 63 Aurora kinase inhibitor 63 Phase 2b clinical 63 NS4A 63 Oral NKTR 63 ChronVac C R 63 Phase IIb clinical 63 randomized Phase 2b 63 interferon alfa 63 Rigel R# 63 satraplatin 63 Bicifadine 63 oblimersen 63 OHR/AVR# 63 resistant ovarian cancer 63 plus Copegus R 63 #I TM# 63 plasma kallikrein inhibitor 63 VELCADE melphalan 63 liver metastases 63 CCX# B 63 zanolimumab 63 HCV polymerase inhibitors 63 Xeloda ® 63 TKM ApoB 63 ELND# 63 ribavirin RBV 63 veltuzumab 63 INT# [002] 63 TORISEL 63 paclitaxel Taxol R 63 Combination REOLYSIN R 63 bortezomib Velcade 63 ara C 63 TKB# 63 delafloxacin 63 Pharmacokinetics PK 63 Ocrelizumab 63 Ceflatonin R 63 cancer mCRC 63 refractory indolent non 63 ZACTIMA 63 incyclinide 63 brostallicin 63 CIMZIA ™ 63 preclinical studies 63 bosutinib 63 imetelstat GRN#L 63 CD3 monoclonal antibody 63 subcutaneous PRO 63 angiogenesis inhibitor 63 Belinostat 63 ocular formulation 63 PEG IFN 63 SPRYCEL ® 63 AEZS 63 D aspartate NMDA receptor 63 5 HT6 receptor 63 retaspimycin 63 oncolytic virus therapies 63 Immunotherapeutic 63 OvaRex ® MAb 63 antitumor effect 63 PREZISTA r 63 KRAS mutations 63 SinuNase ™ 63 follicular NHL 63 pharmacodynamic 63 davunetide intranasal AL 63 NPC 1C 63 cisplatin gemcitabine 63 CD# expressing 63 sarcoma melanoma 63 refractory Hodgkin lymphoma 63 dirucotide 63 interleukin IL -# 63 GAMMAGARD 63 taxane chemotherapy 63 PEG PAL 63 Abiraterone acetate 63 Talactoferrin 63 humanised monoclonal antibody 63 acyclovir Lauriad R 63 immunotherapeutic agent 63 gemcitabine Gemzar ® 63 recurrent metastatic 63 treatment naive genotype 63 T DM1 63 Doxil ® 63 Randomized Phase II 63 Albuferon TM 63 CUDC 63 IFN α 63 Trofex TM 63 Maximum Tolerated Dose MTD 63 samalizumab 63 monotherapy 63 Phase 1b clinical 63 nucleoside 63 fallopian tube cancers 63 metastatic pancreatic 63 Anti Tumor Activity 63 Vidaza azacitidine 63 GLPG# 63 dacarbazine DTIC 63 advanced unresectable 63 MetMAb 63 candidate AQ4N 63 mCRC patients 63 Zenvia ™ 63 trastuzumab emtansine T DM1 63 vosaroxin 63 Zerenex 63 Motesanib 63 EDEMA3 trial 63 selective modulator 63 lymphoid malignancies 63 synthetic retinoid 63 DOS# 63 EZN 63 Aclidinium 63 dexpramipexole 63 vorinostat 63 lymphoma CTCL 63 drug pipeline TAFA# 63 Xcellerated T Cells 63 CTCE 63 Canvaxin 63 L MTP PE 63 rHuPH# 63 lomitapide 63 gemcitabine carboplatin 63 Aptivus ® 63 sapacitabine CYC# 63 dose escalation study 63 therapeutic monoclonal antibody 63 TAFA# 63 phase Ib clinical 63 TransVax TM 63 tesetaxel 63 CDK cyclin dependent 63 kinase inhibitor 63 Antiviral Activity 63 Epothilones 63 Triolex 63 Aurora Kinase 63 MOR# 63 XOMA 3AB 63 luteinizing hormone releasing 63 Phase IIa trials 63 Apoptone 63 indibulin 63 XL# inhibits 63 monoclonal antibody conjugated 63 indolent NHL 63 cancer neuroendocrine tumor 63 Vilazodone 63 GLYX 63 oral nucleoside analogue 63 Deforolimus 63 Interferon alpha 63 CRx 63 trabectedin 63 Taxotere ® 63 Trastuzumab DM1 63 Azedra ™ 63 TG# [001] 63 preclinical efficacy 63 RLY# 63 MDS AML 63 VEGF inhibitors 63 Marqibo TM 63 orally dosed 63 ATL# [001] 63 μg dose 63 panitumumab Vectibix 63 BiovaxID TM 63 refractory prostate cancer 63 Triapine 63 Tarceva erlotinib 63 AVOREN 63 EGFr 63 antiangiogenic therapy 63 IMPDH inhibitor 63 dose escalation phase 63 JAK2 inhibitors 63 myelofibrosis polycythemia vera 63 ONCONASE R 63 dacetuzumab SGN 63 GSK# [001] 63 YONDELIS R 63 BiTE ® 63 APD# 63 Velcade bortezomib 63 DOXIL 63 pharmacodynamic markers 63 Intravenous CP 63 human IgG1 monoclonal 63 bevacizumab Avastin 63 GPNMB 63 Tavocept 63 Initiate Phase 63 allosteric modulator NAM 63 NEUGENE 63 etoposide 63 Protexia ® 63 Phase IIa clinical 63 motexafin gadolinium Injection 63 Hsp# inhibitors 63 bardoxolone 63 investigational HCV polymerase 63 GW# [003] 63 medullary thyroid cancer 63 hormone LHRH antagonist 63 Cloretazine R 63 NSCLC 63 Virulizin R 63 evaluable patients 63 heavily pretreated patients 62 personalized immunotherapy 62 Phase 1b clinical trials 62 FGFR 62 imatinib Gleevec 62 investigational protease inhibitor 62 MAXY alpha 62 alefacept 62 previously untreated follicular 62 Presents Preclinical Data 62 XL# SAR# 62 Copegus R 62 GVAX R 62 eliglustat tartrate 62 hypoxia activated prodrug 62 SinuNase 62 Roche Chugai s 62 tivozanib 62 Zalypsis 62 pharmacokinetic interactions 62 S/GSK# 62 mg kg dose 62 CINQUIL 62 Civacir 62 tyrosine kinase inhibitors 62 cariprazine 62 highly immunogenic 62 EGFr expressing metastatic colorectal 62 MORAb 62 tamibarotene 62 histone deacetylase inhibitor 62 liposomal doxorubicin 62 Telik logo TELINTRA 62 pediatric acute lymphoblastic 62 investigational compounds 62 advanced carcinoid